⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Beta3-Adrenergic Receptor Targeting
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-29 — Vibegron for ENergy Thinking and Resilience in Aging: Vibegron (GEMTESA), an approved β3-agonist, entering a 12-week RCT repurposed for energy metabolism and cardiometabolic/physical/cognitive endpoints in older adults with obesity — extends the β3-agonist longevity-indication pipeline beyond mirabegron brown-fat work. [human-rct] (novelty: 3)
- 2026-09-25 — An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.: cross-connection with zfp423-aso-thermogenesis: Both target white-adipose beiging/thermogenesis as a metabolic-health lever; ZFP423 ASO acts via derepression of brown/beige identity rather than adrenergic signaling. (novelty: 4)
Open questions
Related
Contributing findings
Vibegron for ENergy Thinking and Resilience in Aging
29-sep-2026
novelty 3
per-area 3
strengthens
Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women
28-jul-2026
novelty 2
per-area 2
introduces